Press Release Archive
-
IMBRUVICA® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic LeukemiaIMBRUVICA® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia· Follow-up data from Phase 3 E1912 study (Abstract #33) evaluating the investigational use of IMBRUVICA® in combination with rituximab versus fludarabine, cyclophosphamide and rituximab showed statistically significant difference in progression-free survival (PFS) and overall survival (OS) were maintained in previously untreated patients (ages 70 or younger) with chronic lymphocytic leukemia (CLL)
· Integrated analysis from RESONATETM and RESONATETM-2 studies in CLL (Abstract #3054) reported long-term PFS, OS and response rates with earlier treatment with IMBRUVICA®
· IMBRUVICA® plus venetoclax data from Phase 2 CAPTIVATE study (Abstract #35) showed high rates of undetectable minimal residual disease (uMRD) in peripheral blood (75 percent of patients) and in bone marrow (72 percent of patients) in previously untreated patients with CLL for time-limited, MRD-guided combination regimen -
Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple MyelomaJanssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple MyelomaResults from Phase 1b/2 CARTITUDE-1 to premiere in oral presentation at ASH 2019 (Abstract #577)
-
Janssen to Acquire Investigational Bermekimab from XBiotechJanssen to Acquire Investigational Bermekimab from XBiotechClinical Stage, First-in-Class Anti-IL-1a Antibody for Atopic Dermatitis and Hidradenitis Suppurativa
-
Janssen Announces BCMA CAR-T Therapy JNJ-4528 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Relapsed or Refractory Multiple MyelomaJanssen Announces BCMA CAR-T Therapy JNJ-4528 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Relapsed or Refractory Multiple MyelomaNewest designation for JNJ-4528 is supported by Phase 1b/2 CARTITUDE-1 study in adults with relapsed or refractory multiple myeloma
Initial results from CARTITUDE-1 study to premiere at the American Society of Hematology Annual Meeting -
Johnson & Johnson Announces Commitment to Support Republic of Rwanda’s Preparedness Against Ebola OutbreakJohnson & Johnson Announces Commitment to Support Republic of Rwanda’s Preparedness Against Ebola OutbreakUp to 200,000 Regimens of Janssen’s Investigational Ebola Vaccine to be Supplied to Rwanda for Use in Border Region near Democratic Republic of the Congo (DRC)
-
Johnson & Johnson Names Hubert Joly, Executive Chairman of Best Buy and Mark A. Weinberger, Former EY Global Chairman and CEO to its Board of DirectorsJohnson & Johnson Names Hubert Joly, Executive Chairman of Best Buy and Mark A. Weinberger, Former EY Global Chairman and CEO to its Board of Directors
-
Company Investigation Confirms No Asbestos in Johnson’s Baby PowderCompany Investigation Confirms No Asbestos in Johnson’s Baby PowderMore Than 150 Tests Show No Asbestos
-
Ethicon Launches VISTASEAL Fibrin Sealant (Human) to Manage Bleeding During SurgeryEthicon Launches VISTASEAL Fibrin Sealant (Human) to Manage Bleeding During SurgeryNext Generation Device Simplifies Setup and May Save Valuable Operating Room TimeVISTASEAL is first innovation to emerge from Ethicon’s strategic partnership with Grifols, a pioneer in the plasma industry
-
Johnson & Johnson Announces Winners of Champions of Science® Storytelling Challenge – Latin America and the Caribbean EditionJohnson & Johnson Announces Winners of Champions of Science® Storytelling Challenge – Latin America and the Caribbean EditionProgram Spotlights Scientific Contributions and Personal Journeys of Scientists Across the Region
-
New Analysis from Landmark CREDENCE Study Shows the Efficacy and Safety Profiles of INVOKANA® (canagliflozin) are Consistent Across Various Levels of Kidney FunctionNew Analysis from Landmark CREDENCE Study Shows the Efficacy and Safety Profiles of INVOKANA® (canagliflozin) are Consistent Across Various Levels of Kidney FunctionAnalysis shows consistent renal and cardiovascular benefit when treated with INVOKANA® even when patients had moderate to severe renal deficiencyINVOKANA® is the only diabetes medicine indicated to slow the progression of diabetic nephropathy (also known as DKD) and reduce the risk of hospitalization for heart failure in patients with type 2 diabetes (T2D) and DKDData announcement comes after recent news of the company’s commercial partnership with Vifor Pharma, leader in nephrology, to jointly commercialize the INVOKANA® DKD indication in the United States